Product Images Gemcitabine

This is a figure from a study (Study 2) that shows Kaplan-Meier curves for time to documented disease progression for two treatments: Gemcitabine/Paclitaxel and Paclitaxel alone. The figure includes the median time to documented disease progression which is 52 months for Gemcitabine/Paclitaxel and 2.8 months for Paclitaxel alone. The log rank p-value is <0.0001, indicating a statistically significant difference in time to documented disease progression between the two treatments. The x-axis of the figure is labeled as "Time to Documented Disease Progression (Months)" and the y-axis is labeled with the number of participants who still had not experienced documented disease progression over time.*

This appears to be a graph indicating the fraction of patients surviving over time for two different treatments (Gemcitabine and 5FU) and a control group (labeled "o S"). The x-axis represents survival time in months and the y-axis represents the fraction of patients surviving. Unfortunately, without more context or a clearer image, it is difficult to provide further information.*

The text is describing a medication called Gemcitabine Injection, which is administered intravenously and must be diluted before use. Each vial contains 200mg of gemcitabine, which is equal to 102.27mg of gemcitabine hydrochloride. The medication is stored refrigerated and discarded if unused. The container does not contain natural rubber latex and is sterile, non-pyrogenic, and preservative-free. The text also includes some cautionary statements about handling the medication, which can be potentially toxic.*

Gemcitabine is a cytotoxic agent used for intravenous infusion, which must be diluted before use. The medication is contained in a single-dose vial of 0.3 mL, and any unused portion should be discarded. The concentration is 38mg per mL. The prescription should be used only after a physician's assessment, and only following an intravenous infusion. The remaining text is not legible.*

Gemcitabine is a potent cytotoxic agent used for intravenous infusion. Each vial contains 1 gram of gemcitabine and water for injection. The vial should be stored in the refrigerator between 2 and 8°C. The gemcitabine must be diluted before use and should not be frozen. After using, discard the unused portion of gemcitabine. Caution should be taken while using this agent to avoid inhaling particles. There are some instructions available on the package for dosing and administration.*

Gemcitabine is a pharmaceutical product administered intravenously. It is available in single-dose vials containing 228-238mg of the active ingredient per 5.26mL. The product should be refrigerated between 2°C and 8°C and must be diluted before use. Gemcitabine is a cytotoxic agent, and caution should be exercised when administering it to patients. The information provided includes warnings about the potential dangers of inhaling the drug's particles and an assurance that the medication's vials do not contain natural rubber. The text also includes manufacturing information about the pharmaceutical product and instructions for healthcare professionals.*